Kimberly Vanover Net Worth

The estimated Net Worth of Kimberly E. Vanover is at least $4.27 Million dollars as of 4 January 2019. Ms. Vanover owns over 10,156 units of Intra-Cellular Therapies Inc stock worth over $2,022,521 and over the last 10 years he sold ITCI stock worth over $143,748. In addition, he makes $2,107,590 as Senior Vice President and Early Stage Clinical Development and Translational Medicines at Intra-Cellular Therapies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Vanover ITCI stock SEC Form 4 insiders trading

Kimberly has made over 4 trades of the Intra-Cellular Therapies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 10,156 units of ITCI stock worth $116,997 on 4 January 2019.

The largest trade he's ever made was exercising 18,750 units of Intra-Cellular Therapies Inc stock on 15 December 2016 worth over $27,375. On average, Kimberly trades about 2,771 units every 68 days since 2014. As of 4 January 2019 he still owns at least 27,068 units of Intra-Cellular Therapies Inc stock.

You can see the complete history of Ms. Vanover stock trades at the bottom of the page.

Kimberly Vanover biography

DR. Kimberly E. Vanover Ph.D. serves as Senior Vice President, Early Stage Clinical Development and Translational Medicines of the Company. She has over 25 years of experience concentrated in pharmaceutical compliance and legal matters. In prior roles, Ms. Sheehy led compliance functions at Mallincrodt, as Senior Vice President, Chief Compliance Officer, and at Sanofi as Vice President, Head, North America Compliance. Prior to those roles, she held various roles in the legal function with increasing responsibility. Ms. Sheehy was also in private practice at Riker, Danzig, Scherer, Hyland & Perretti LLP and was an adjunct Professor of Law at the Seton Hall Law School. Ms. Sheehy received her bachelor’s degree from Seton Hall University and her Juris Doctor degree from Seton Hall Law School.

What is the salary of Kimberly Vanover?

As the Senior Vice President and Early Stage Clinical Development and Translational Medicines of Intra-Cellular Therapies Inc, the total compensation of Kimberly Vanover at Intra-Cellular Therapies Inc is $2,107,590. There are 5 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.

What's Kimberly Vanover's mailing address?

Kimberly's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK, NY, 10032.

Insiders trading at Intra-Cellular Therapies Inc

Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus, and Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.

What does Intra-Cellular Therapies Inc do?

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Complete history of Ms. Vanover stock trades at Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc executives and stock owners

Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:

• Sharon Mates,
  Chairman of the Board, President, Chief Executive Officer
• Mark Neumann,
  Executive Vice President, Chief Commercial Officer
• Michael Halstead,
  Executive Vice President, General Counsel and Secretary
• Lawrence Hineline,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
• Robert Davis,
  Senior Vice President and Chief Scientific Officer
• Kimberly Vanover,
  Senior Vice President, Early Stage Clinical Development and Translational Medicines
• Dr. Sharon Mates,
  Co-Founder, Chairman, CEO & Pres
• Mark Neumann,
  EVP & Chief Commercial Officer
• Michael I. Halstead J.D.,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Suresh K. Durgam M.D.,
  Sr. VP & Chief Medical Officer
• Lawrence J. Hineline CPA, CPA,
  Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
• Robert Van Nostrand,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Christopher Alafi,
  Independent Director
• Rory Riggs,
  Independent Director
• Richard Lerner,
  Independent Director
• Michael Olchaskey,
  Senior Vice President, Head of Regulatory Affairs
• Suresh Durgam,
  Chief Medical Officer
• John Bardi,
  Senior Vice President - Market Access, Policy and Government Affairs
• Karen Patruno Sheehy Esq.,
  Sr. VP & Chief Compliance Officer
• Juan Fernando Sanchez,
  VP of Corp. Communications & Investor Relations
• Dr. Robert E. Davis Ph.D.,
  Sr. VP & Chief Scientific Officer
• Moshe Alafi,
  10% owner
• Capital Co Llc Alafi,
  10% owner
• Juan F. Sanchez,
  VP, Corp. Communications & IR
• Allen A. Fienberg,
  VP of Business Development
• Lawrence P. Wennogle,
  Vice President, Drug Discovery
• Michael Rawlins,
  Director
• Eduardo Rene Salas,
  
• Sanjeev Narula,
  Executive Vice President & CFO